227 related articles for article (PubMed ID: 33964212)
1. Specific inhibition of oncogenic RAS using cell-permeable RAS-binding domains.
Nomura TK; Heishima K; Sugito N; Sugawara R; Ueda H; Yukihiro A; Honda R
Cell Chem Biol; 2021 Nov; 28(11):1581-1589.e6. PubMed ID: 33964212
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of RAS: proven and potential vulnerabilities.
Zuberi M; Khan I; O'Bryan JP
Biochem Soc Trans; 2020 Oct; 48(5):1831-1841. PubMed ID: 32869838
[TBL] [Abstract][Full Text] [Related]
3. Conformation-specific inhibitors of activated Ras GTPases reveal limited Ras dependency of patient-derived cancer organoids.
Wiechmann S; Maisonneuve P; Grebbin BM; Hoffmeister M; Kaulich M; Clevers H; Rajalingam K; Kurinov I; Farin HF; Sicheri F; Ernst A
J Biol Chem; 2020 Apr; 295(14):4526-4540. PubMed ID: 32086379
[TBL] [Abstract][Full Text] [Related]
4. Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.
Shin SM; Kim JS; Park SW; Jun SY; Kweon HJ; Choi DK; Lee D; Cho YB; Kim YS
Sci Adv; 2020 Jan; 6(3):eaay2174. PubMed ID: 31998840
[TBL] [Abstract][Full Text] [Related]
5. Drugging the Undruggable: Advances on RAS Targeting in Cancer.
Molina-Arcas M; Samani A; Downward J
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34200676
[TBL] [Abstract][Full Text] [Related]
6. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State.
Patricelli MP; Janes MR; Li LS; Hansen R; Peters U; Kessler LV; Chen Y; Kucharski JM; Feng J; Ely T; Chen JH; Firdaus SJ; Babbar A; Ren P; Liu Y
Cancer Discov; 2016 Mar; 6(3):316-29. PubMed ID: 26739882
[TBL] [Abstract][Full Text] [Related]
7. Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.
Shin SM; Choi DK; Jung K; Bae J; Kim JS; Park SW; Song KH; Kim YS
Nat Commun; 2017 May; 8():15090. PubMed ID: 28489072
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor.
Janes MR; Zhang J; Li LS; Hansen R; Peters U; Guo X; Chen Y; Babbar A; Firdaus SJ; Darjania L; Feng J; Chen JH; Li S; Li S; Long YO; Thach C; Liu Y; Zarieh A; Ely T; Kucharski JM; Kessler LV; Wu T; Yu K; Wang Y; Yao Y; Deng X; Zarrinkar PP; Brehmer D; Dhanak D; Lorenzi MV; Hu-Lowe D; Patricelli MP; Ren P; Liu Y
Cell; 2018 Jan; 172(3):578-589.e17. PubMed ID: 29373830
[TBL] [Abstract][Full Text] [Related]
9. RAS-targeted therapies: is the undruggable drugged?
Moore AR; Rosenberg SC; McCormick F; Malek S
Nat Rev Drug Discov; 2020 Aug; 19(8):533-552. PubMed ID: 32528145
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a Direct Ras Inhibitor by Screening a Combinatorial Library of Cell-Permeable Bicyclic Peptides.
Trinh TB; Upadhyaya P; Qian Z; Pei D
ACS Comb Sci; 2016 Jan; 18(1):75-85. PubMed ID: 26645887
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological strategies to target oncogenic KRAS signaling in pancreatic cancer.
Chuang HC; Huang PH; Kulp SK; Chen CS
Pharmacol Res; 2017 Mar; 117():370-376. PubMed ID: 28077300
[TBL] [Abstract][Full Text] [Related]
12. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.
Yurugi H; Marini F; Weber C; David K; Zhao Q; Binder H; Désaubry L; Rajalingam K
Oncogene; 2017 Aug; 36(33):4778-4789. PubMed ID: 28414306
[TBL] [Abstract][Full Text] [Related]
13. Drugging K-Ras
Ni D; Li X; He X; Zhang H; Zhang J; Lu S
Pharmacol Ther; 2019 Oct; 202():1-17. PubMed ID: 31233765
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Bicyclic Peptidyl Pan-Ras Inhibitor.
Buyanova M; Cai S; Cooper J; Rhodes C; Salim H; Sahni A; Upadhyaya P; Yang R; Sarkar A; Li N; Wang QE; Pei D
J Med Chem; 2021 Sep; 64(17):13038-13053. PubMed ID: 34415745
[TBL] [Abstract][Full Text] [Related]
15. MUC1-C confers EMT and KRAS independence in mutant KRAS lung cancer cells.
Kharbanda A; Rajabi H; Jin C; Alam M; Wong KK; Kufe D
Oncotarget; 2014 Oct; 5(19):8893-905. PubMed ID: 25245423
[TBL] [Abstract][Full Text] [Related]
16. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-effector interaction.
Shima F; Yoshikawa Y; Ye M; Araki M; Matsumoto S; Liao J; Hu L; Sugimoto T; Ijiri Y; Takeda A; Nishiyama Y; Sato C; Muraoka S; Tamura A; Osoda T; Tsuda K; Miyakawa T; Fukunishi H; Shimada J; Kumasaka T; Yamamoto M; Kataoka T
Proc Natl Acad Sci U S A; 2013 May; 110(20):8182-7. PubMed ID: 23630290
[TBL] [Abstract][Full Text] [Related]
17. Targeting RAS-RAF pathway significantly improves antitumor activity of Rigosertib-derived platinum(IV) complexes and overcomes cisplatin resistance.
Liu Z; Wang M; Wang H; Fang L; Gou S
Eur J Med Chem; 2020 May; 194():112269. PubMed ID: 32248002
[TBL] [Abstract][Full Text] [Related]
18. Pan-RAS inhibitors: Hitting multiple RAS isozymes with one stone.
Coley AB; Ward A; Keeton AB; Chen X; Maxuitenko Y; Prakash A; Li F; Foote JB; Buchsbaum DJ; Piazza GA
Adv Cancer Res; 2022; 153():131-168. PubMed ID: 35101229
[TBL] [Abstract][Full Text] [Related]
19. Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.
Huynh MV; Campbell SL
Mini Rev Med Chem; 2016; 16(5):383-90. PubMed ID: 26423694
[TBL] [Abstract][Full Text] [Related]
20. Probing RAS Function with Monobodies.
Khan I; O'Bryan JP
Methods Mol Biol; 2021; 2262():281-302. PubMed ID: 33977484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]